<DOC>
	<DOCNO>NCT03017495</DOCNO>
	<brief_summary>The main objective phase 1 trial evaluate effect food pharmacokinetics ( i.e . long much compound present blood ) ACT-541468 evaluate whether ACT-541468 affect pharmacokinetics midazolam , CYP3A4 substrate .</brief_summary>
	<brief_title>A Clinical Study Investigate Potential Interactions Between Food ACT-541468 Between ACT-541468 Midazolam</brief_title>
	<detailed_description>Food effect assess compare pharmacokinetic ( PK ) parameter single dose ACT-541468 fast ( Treatment B ) fed ( Treatment C ) condition . Potential CYP3A4 inhibit / inducing effect ACT-541468 assess compare PK parameter midazolam alone ( Treatment A ) midazolam give single dose ACT-541468 ( Treatment B ) multiple dose ACT-541468 ( Treatment D ) .</detailed_description>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Signed informed consent form Male subject age 18 45 year ( inclusive ) screen Body mass index ( BMI ) 18.0 30.0 kg/m2 ( inclusive ) screen Healthy basis physical examination , cardiovascular assessment laboratory test Any contraindication study treatment History clinical evidence disease medical / surgical condition treatment , may put subject risk participation study may interfere absorption , distribution , metabolism excretion study treatment History narcolepsy cataplexy modify Swiss narcolepsy scale total score &lt; 0 Any circumstance condition , , opinion investigator , may affect subject 's full participation study compliance protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>food-drug interaction</keyword>
	<keyword>drug-drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>